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Abstract
Background: 14-3-3 sigma (σ) promotes G2/M cell cycle arrest by sequestering cyclin B1-CDC2
complex in cytoplasm. Down-regulation of 14-3-3σ, which has been demonstrated in various
carcinomas, may contribute to malignant transformation. However, the exact role of 14-3-3σ in
the pathogenesis of vulvar carcinoma is not fully characterized, and the prognostic impact of 14-3-
3σ protein expression is still unknown.
Methods: We investigated the 14-3-3σ expression in a series of 302 vulvar squamous cell
carcinomas using immunohistochemistry and its associations with clinicopathological factors and
clinical outcome.
Results: In cytoplasm, nucleus and cytoplasm/nucleus of vulvar carcinomas high 14-3-3σ protein
expression was found in 72%, 59% and 75% of the carcinomas, respectively, and low levels in 28%,
41% and 25% of the cases, respectively. High level of 14-3-3σ in cytoplasm, nucleus and cytoplasm/
nucleus was significantly correlated to large tumor diameter (p = 0.001, p = 0.002 and p = 0.001,
respectively) and deep invasion (p = 0.01, p = 0.001 and p = 0.007, respectively). Variations of 14-
3-3σ protein expression were not associated to disease-specific survival.
Conclusion: Our results indicate that 14-3-3σ may be involved in the development of a subset of
vulvar squamous cell carcinomas by down-regulation of 14-3-3σ protein. Neither cytoplasmic nor
nuclear level of 14-3-3σ expression was associated with prognosis.
Background
Vulvar carcinoma represents 3–5% of all female genital
cancer [1] and was previously considered a disease of eld-
erly women. However, we see an increase in the incidence
of vulvar carcinomas among younger women in recent
years [2]. Considerable morbidity is often followed radi-
cal surgery, which has been the standard treatment [3].
Individualized therapy has been introduced to raise the
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apy urge us to search for factors involved in tumorigenesis
as well as identification of new tumor markers for therapy.
In mammals, 14-3-3 proteins are composed of a highly
conserved multigene family of small acidic proteins,
including seven 14-3-3 isoforms (β, ε, γ, η, σ, τ, ζ) [5]. As
a phosphoserine/phosphothreonine-binding protein, 14-
3-3s bind to proteins within their RSXpSXP and RX(Y/F)
XpSXP sequences (pS represents phosphoserine or phos-
phothreonine) [6] and thereby play an important role in
various cellular processes such as altering enzymatic activ-
ity, subcellular localization, protein-protein interactions,
dephosphorylation, and proteolysis of individual target
proteins [7-9].
14-3-3σ, also named stratiffin, is mostly expressed in
human epithelial cells [8]. Responsive to DNA damage,
14-3-3σ expression is induced in a p53-dependent man-
ner [10-12]. 14-3-3σ sequesters cyclin B1-CDC2 complex
in cytoplasm, and prevents its entry into nucleus resulting
in G2/M cell cycle arrest [10,12]. Furthermore, 14-3-3σ
can link to CDK2 and CDK4 and block the cell cycle entry
[13]. Thus, 14-3-3σ acts as a negative regulator of cell cycle
progression and is linked to cancer [14].
Epigenetic change in the 14-3-3σ gene by CpG hyper-
methylation followed by down-regulation of 14-3-3σ
expression has been demonstrated in various carcinomas
[15-22]. Furthermore, in breast carcinoma [22], endome-
trial carcinoma [23] and colorectal carcinoma [24] 14-3-
3σ expression was found to be associated with the
patients' clinical outcome. In a previous study, including
a limited number of vulvar carcinomas, appropriately
60% of the cases revealed CpG methylation in the 14-3-3σ
gene [25]. However, the expression of the 14-3-3σ protein
and its connection with prognosis has still not been
reported in vulvar carcinoma patients. Thus, we intended
to study the 14-3-3σ expression in a series of 302 vulvar
squamous cell carcinomas in order to disclose the correla-
tion between 14-3-3σ expression and its prognostic value.
Methods
Patient materials
A retrospective study was performed, in which 302
patients with squamous cell carcinoma of vulvar under-
went surgery at The Norwegian Radium Hospital in the
period 1977–2006. Before surgery, radiotherapy was
given to 9 (3%) of the patients, additionally, 3 (1%) of the
patients received chemotherapy. Radical vulvectomy was
performed on 201 (67%) of the patients. Postoperative
irradiation was given to 63 (21%), chemotherapy to 3
(1%) and irradiation/chemotherapy to 4 (1%) of the
patients. One hundred and eight (36%) patients suffered
from a relapse. The median age at diagnosis was 74 years
(range 35–96 years). All patients were followed until
death or 31. December, 2006. One hundred and twenty
patients (40%) died of vulvar cancer. The median follow-
up time for all patients was 52 months (range 0.4–346
months), whereas the median follow-up time for patients
alive at last observation was 131 months (range 11–346
months). All tumors were staged according to the Interna-
tional Federation of Gynecology and the Obstetrics
(FIGO) classification [26]. The Regional Committee for
Medical Research Ethics South of Norway (S-06012), The
Social- and Health Directorate (04/2639 and 06/1478)
and The Data Inspectorate (04/01043) approved the
study.
Histological specimens were reviewed by one of the
authors (J.M.N.) who had no access to clinical informa-
tion. The tumors were classified according to World
Health Organization recommendations [27] and 284
(94%) were keratinizing/nonkeratinizing, 14 (5%) were
basaloid and 4 (1%) were veruccoid. The primary tumors
of the patients have previously been investigated for the
expression of p53, p16, p21, p27, p14, and the cyclins A,
D1, D3 and E and human papillomavirus (HPV) [28-31].
Table 1 provides a detailed description of the tumor char-
acteristics. As controls, samples of normal vulva were col-
lected form 11 patients undergone surgery for benign
gynecological diseases.
Cell Line
Human vulvar squamous cell carcinoma cell lines SW-954
(ATCC, Manassas, VA, U.S.A) and CAL-39 (DSMZ, Ger-
many) were grown as monolayer cultures recommended
by the suppliers. For RNA analysis, cells from monolayer
culture were harvested by using 0.01 M EDTA solution
and washed in PBS. For immunohistochemstry, cells were
fixed in 4% formalin and embedded in paraffin.
Immunohistochemical method
Sections (4 μm) from formalin-fixed, paraffin-embedded
tissue were processed for immunohistochemistry using
the Dako EnVision™ + System, Peroxidase (DAB) (K4007,
Dako Corporation, CA, U.S.A). Deparaffinized sections
were microwaved in 10 mM citrate buffer pH 6.0 to
unmask the epitopes and treated with 0.3% hydrogen per-
oxidase (H2O2) for 5 min to block endogenous peroxi-
dase. Monoclonal 14-3-3σ antibody (clone 1433S01,
1:75, 2.7 μg IgG1/ml) from NeoMarkers, CA, U.S.A were
applied on the sections for 30 min at room temperature.
The primary antibody is highly specific to 14-3-3σ and
shows no cross-reaction with other isoforms of 14-3-3
(information from NeoMarkers). Subsequently, the slides
were incubated with horseradish peroxidase (HRP)
labeled polymer conjugated goat-anti-mouse for 30 min,
followed by incubation with 3'3-diaminobenzidine tet-
rahydrochloride (DAB) for 10 min. The sections werePage 2 of 9
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BMC Cancer 2008, 8:308 http://www.biomedcentral.com/1471-2407/8/308Table 1: 14-3-3σ immunostaining in relation to clinicopathological variables
Variables Total Cytoplasm Nucleus Cytoplasm and nucleus
n Low High (%) p1 Low High (%) p1 Low High (%) p1
Age 0.21 0.96 0.06
25–69 121 39 82 (68) 49 72 (60) 38 83 (69)
70–84 147 34 113 (77) 62 85 (58) 28 119 (81)
85+ 34 11 23 (68) 14 20 (59) 10 24 (71)
FIGO 0.26 0.49 0.08
Ia 11 2 9 (82) 4 7 (64) 2 9 (82)
Ib 37 16 21 (57) 19 18 (49) 16 21 (57)
II 110 28 82 (75) 43 67 (61) 22 88 (80)
III 121 32 89 (74) 46 75 (62) 30 91 (75)
IV 19 5 14 (74) 10 9 (47) 5 14 (74)
Not available 4
Lymph node metastasis 0.42 0.97 0.54
None 137 41 96 (70) 55 82 (60) 36 101 (74)
Unilateral 76 18 58 (76) 31 45 (59) 17 59 (78)
Bilateral 34 12 22 (65) 13 21 (62) 11 23 (68)
Not available 55
Tumour diameter (cm) 0.001 0.002 0.001
0.3–2.5 92 34 58 (63) 50 42 (46) 33 59 (64)
2.6–4.0 94 30 64 (68) 35 59 (63) 25 69 (73)
4.1–20.0 100 14 86 (86) 30 70 (70) 12 88 (88)
Not available 16
Tumor differentiation 0.09 0.10 0.08
Well 76 27 49 (65) 39 37 (49) 25 51 (67)
Moderate 154 43 111 (72) 61 93 (60) 39 115 (75)
Poor 72 14 58 (81) 25 47 (65) 12 60 (83)
Depth of invasion (mm) 0.01 0.001 0.007
0.0–4.0 80 32 48 (60) 45 35 (44) 30 50 (63)
4.1–8.0 99 24 75 (76) 38 61 (62) 21 78 (79)
8.1–40.0 112 24 88 (79) 34 78 (70) 21 91 (81)
Not available 11
Infiltration of vessel 0.33 0.50 0.41
No 233 67 166 (71) 99 134 (58) 61 172 (74)
Yes 66 15 51 (77) 25 41 (62) 14 52 (79)
Not available 3
p142 1.00 1.00 0.88
Low (-) 135 98 37 (27) 46 89 (66) 84 51 (38)
High (+) 77 56 21 (27) 26 51 (66) 49 28 (36)
Not available 100
p162 0.63 0.88 0.15
Low (< 5%) 148 40 108 (73) 51 97 (66) 37 111 (75)
High (≥ 5%) 63 15 48 (76) 21 42 (67) 10 53 (84)
Not available 91
p212 0.17 0.87 0.10
Low (-) 122 36 86 (71) 42 80 (66) 32 90 (74)
High (+) 90 19 71 (79) 30 60 (67) 15 75 (84)
Not available 90
p272 0.18 0.56 0.19
Low (< 50%) 164 39 125 (76) 54 110 (67) 33 131 (80)
High (≥ 50%) 48 16 32 (67) 18 30 (63) 14 34 (71)
Not available 90
p532 0.70 0.12 0.93
Low (< 5%) 93 25 68 (73) 26 67 (72) 20 73 (79)
High (≥ 5%) 118 29 89 (75) 45 73 (62) 26 92 (78)
Not available 91
Cyclin A2 0.68 0.09 0.59
Low (< 5%) 61 17 44 (72) 26 35 (57) 15 46 (75)
High (≥ 5%) 151 38 113 (75) 46 105 (70) 32 119 (79)
Not available 90Page 3 of 9
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mounted in Diatex.
Normal skin was included as positive control in all series.
Negative controls included substitution of the mono-
clonal antibody with mouse myeloma protein of the same
subclass and concentration as the monoclonal antibody.
Both nuclear and cytoplasmic staining was considered
positive. Immunostaining was scored on a 3 – tiered scale
for both intensity (absent/weak, 1; moderate, 2; strong, 3)
and extent of staining (percentage of positive tumor cells:
< 10%, 1; 10–50%, 2; > 50%, 3). Scoring results of inten-
sity and extent were multiplied to give a composite score
ranging from 1 to 9 for each section. Protein expression in
cytoplasm was defined as high when composite scores
were ≥ 6, and low when composite scores were < 6,
whereas, protein expression in nucleus were classified as
high when any 14-3-3σ staining was observed in the
tumor and low when no staining was seen. This is based
on staining pattern observed in normal vulvar epithelium.
We later verified all other cutoff values. Examination of
immunostaining was performed by two independent
observers (Z.W. and R.H.) with no knowledge of patient
outcome. All discordant scores were reviewed until final
agreement was obtained. Reproducibility in the semi-
quantitative scoring was controlled. The kappa values
were 0.72 for both extra- and intra-observer variability
when determined on a subset of 40 patients.
Laser captured microdissection (LMC)
Eleven vulvar carcinomas frozened at -70°C were selected
for LMC and RNA isolation.
First, 8 μm frozen sections were fixed in ethanol, stained
with hematoxylin-eosin (HE), dehydrated in graded etha-
nol and zylene and air-dried for 5 min. Then, by using a
PixCell laser capture microscope (Arctrurus Engineering
Inc., Mountain View, CA), 30–200 pure tumor cells were
captured on caps by focal melting of the membrane
through laser activation. The LMC parameters were as fol-
lows, a laser power of 70–80 mW, laser pulse duration of
1.2–3.5 ms, and laser spot size of 7.5–15 μm in diameter.
Finally, the caps with the selected cells were covered with
lysis buffer in Eppendorf tubes and rotated several times
for homogenization before RNA isolation.
RNA isolation
An Absolutely RNA™ Nanoprep Kit (Stratagene Inc. La
Jolla, USA), which was special designed to purify RNA
from 1 to 104 cells, was employed to extract and purify
RNA from cells captured on caps by LCM. Total RNA and
Protein Isolation Kit (Macherey-Nagel, Duren, Germany)
was used to isolate total RNA form cell line SW-954 and
CAL-39 as recommended by the manufacturer.
RT-PCR
Transcriptor First Stand cDNA Synthesis Kit (Roche Inc.,
Mannheim, Germany) was used to synthesis cDNA. The
total reaction volume was 20 μl and the reaction systems
were: (1) RNA from LMC tissues: 4 μl 5 × Transcriptor RT
Reaction Buffer, 0.5 μl Protector Rnase Inhibitor, 0.5 μl
Transcriptor Reverse Transcriptase, 2 μl dNTP Mix (PCR
grade), 1 μl Anchored Oligo (dt) 18 Primer, 2 μl Water
(PCR Grade), and 10 μl RNA. (2) RNA form cell line: 4 μl
5 × Transcriptor RT Reaction Buffer, 0.5 μl Protector Rnase
Inhibitor, 0.5 μl Transcriptor Reverse Transcriptase, 2 μl
dNTP Mix (PCR grade), 1 μl Anchored Oligo (dt)18
Primer, 10 μl Water (PCR Grade), and 2 μl RNA. The reac-
tion condition was: 65°C for 10 min for mixture of cDNA
and primer pre-denaturation, followed by 55°C for 30
min for reverse transcription of RNA, ended by 85°C for
5 min for inaction of reverse transcriptase.
Quantitative Real-Time PCR
Five μl cDNA from LMC samples and 2 μl cDNA from cell
lines were used as templates in subsequent Real-Time
Cyclin D12 0.87 0.75 0.83
Low (-) 156 40 116 (74) 52 104 (67) 34 122 (78)
High (+) 56 15 41 (73) 20 36 (64) 13 43 (77)
Not available 90
Cyclin D32 0.25 0.76 0.69
Low (< 50%) 153 43 110 (72) 51 102 (67) 35 118 (77)
High (≥ 50%) 59 12 47 (80) 21 38 (64) 12 47 (80)
Not available 90
Cyclin E2 0.72 0.64 0.32
Low (< 50%) 173 44 129 (75) 60 113 (65) 36 137 (79)
High (≥ 50%) 39 11 28 (72) 12 27 (69) 11 28 (72)
Not available 90
HPV2 0.87 0.47 0.98
Low (-) 168 44 124 (74) 57 111 (66) 39 129 (77)
High (+) 44 11 33 (75) 15 29 (66) 8 36 (82)
Not available 90
1 Pearson chi-square 2 In previous reports, p53, p16, p21, p27, p14, cyclin A, cyclin D1, cyclin D3, cyclin E and HPV have been studied [28-31].
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Mannheim, Germany) using LightCycler® TaqMan® Master
kit (Roche Inc., Mannheim, Germany) and gene specific
Hydrolysis (TaqMan) Probes, according to the manufac-
turer's instruction. Glyceraldehyde-3-phosphate dehydro-
genase (GAPDH) was used as an internal control for
relative gene expression quantification and for each gene
amplification. Cp values (reading obtained at 530 nm)
were normalized to the Cp of the GAPDH using the Light-
Cycler analysis software. The following sets of primers
were used to amplify gene products for Real-Time PCR
reactions: GAPDH forward-5'-AGC CAC ATC GCT CAG
ACA, reverse-5'-GCC CAA TAC GAC CAA ATC C; 14-3-3σ
forward-5'-GAC ACA GAG TCC GGC ATT G, reverse-5'-
ATG GCT CTG GGG ACA CAC.
Statistical analyses
The association between 14-3-3σ protein expression and
clinicopathologic variables, and that between 14-3-3σ
protein expression and 14-3-3σ mRNA expression levels
were evaluated by the Person χ2 test. The Kaplan and
Meier method and the log-rank test were used to estimate
and compare survival rate. Disease-specific survival was
defined as the interval between diagnosis and death due
to vulvar cancer. A Cox proportional hazards regression
model was used for multivariate evaluation of survival
rates. A backward stepwise regression with a p = 0.05 in
univariate analysis as the inclusion criterion was used. All
calculation was performed using the SPSS 15.0 statistical
software package (SPSS, Chicago, IL). Statistical signifi-
cance was considered as p ≤ 0.05.
Results
14-3-3σ protein expression
In normal vulvar epithelium, none of the 11 cases showed
nuclear 14-3-3σ immunostaining. Nevertheless, high
level of cytoplasmic staining (score ≥ 6) was present in 11/
11 (100%) cases. The 14-3-3σ immunostaining was
found in the basal, parabasal, middle and top layers of the
vulvar epithelium (Figure 1a). In vulvar carcinomas, high
14-3-3σ expression (score ≥ 6) in cytoplasm was found in
218 (72%) cases and low levels in 84 (28%), whereas,
high levels of nuclear immunostaining of 14-3-3σ (any
positive nuclei) were observed in 177 (59%) cases, and
low levels in 125 (41%). High 14-3-3σ expression (score
≥ 6) in cytoplasm/nuclei was found in 226 (75%) cases
and low levels in 76 (25%) (Figure 1b and Table 2).
In the vulvar carcinoma cell lines SW-954 and CAL-39
high levels (score ≥ 6) of cytoplasmic 14-3-3σ immunos-
taining were observed (Figure 1c and 1d).
14-3-3σ mRNA expression and association with 14-3-3σ 
protein levels
Expression of 14-3-3σ mRNA was found in all laser-
microdissection-captured vulvar carcinomas and in both
vulvar carcinoma cell lines SW-954 and CAL-39. How-
ever, the mRNA expression levels were variable (Figure 2).
No significant association was observed between levels of
14-3-3σ mRNA and 14-3-3σ protein expression in cyto-
plasm (p = 0.242), nucleus (p = 1.000) or cytoplasm/
nucleus (p = 0.242) in vulvar carcinomas. Both cell lines
showed low levels of 14-3-3σ mRNA expression and did
not correlate to the high (score ≥ 6) 14-3-3σ protein
expression.
14-3-3σ immunostaining in relation to clinicopathological 
parameters and patients survival
The levels of 14-3-3σ immunostaining in relation to clin-
icopathological parameters are shown in Table 1. High
expression of 14-3-3σ in cytoplasm, nucleus and cyto-
plasm/nucleus were significantly correlated to large tumor
diameter (p = 0.001, p = 0.002 and p = 0.001, respectively)
and deep invasion (p = 0.01, p = 0.001 and p = 0.007,
respectively). 14-3-3σ was neither associated to the cell
cycle proteins p14, p16, p21, p27, p53 and cyclin A1, D1,
D3 and E, nor to HPV.
In univariate analysis, with the variables defined in Table
1, age (p = 0.002), tumor diameter (p < 0.001), depth of
invasion (p = 0.007), lymph node metastasis (p < 0.001),
FIGO (p < 0.001) and infiltration of vessel (p < 0.001)
were correlated to disease-specific survival. There was no
significant association between disease-specific survival
and 14-3-3σ expression in cytoplasm (p = 0.23), nuclear
(p = 0.51) and cytoplasm/nuclear (p = 0.21). In multivar-
iate analysis, FIGO, lymph node metastasis, age and depth
of invasion were of independent prognostic significance
(Table 3).
Discussion
In our study normal vulvar squamous epithelium showed
high cytoplasmic positivity for 14-3-3σ protein in the
whole layer, which is similar to the findings in normal
squamous epithelium of skin, esophagus and cervix [32].
However, in normal tongue 14-3-3σ immunoreactivity
was often weak in the basal layer compared to that of the
middle and top layers [32]. One explanation for these dif-
ferent results may be that p63 is extensively present in low
layer of epidermal tongue [33], and that ΔNp63 depress
14-3-3σ expression [34] by controlling the p53-binding
site of 14-3-3σ. However, when keratinocytes become
more differentiated, and less ΔNp63 is produced, 14-3-3σ
expression resume.
Mhawech et al [35] have studied the expression of 14-3-
3σ protein in neoplastic tissues of urological and gyneco-Page 5 of 9
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seen in urothelial bladder carcinoma (97.8%), squamous
cell carcinoma of cervix (66.7%), endometrial adenocarci-
noma (56.5%), prostatic adenocarcinoma (55.0%), renal
papillary tumor (50%), ovarian adenocarcinoma
(33.3%), and breast carcinoma (23.3%). In our study,
positive 14-3-3σ staining was identified in cytoplasm
and/or nucleus in 99.3% of vulvar carcinomas.
Gasco et al [25] identified methylation within the 14-3-3σ
gene in approximately 60% of vulvar carcinomas. How-
ever, in the present study low levels of 14-3-3σ protein
was found in only 25% of vulvar carcinomas. We have
identified 14-3-3σ methylation in 57/57 (100%) vulvar
carcinomas and 5/5 (100%) normal blood samples,
whereas the two vulvar squamous cell carcinoma cell lines
Expression of 14-3-3σ proteinFigure 1
Expression of 14-3-3σ protein. Expression of 14-3-3σ protein in normal vulvar epithelium (a), vulvar carcinoma (b), SW-
954 cell line (c) and CAL-39 cell line (d).
Table 2: Immunostaining results for 14-3-3σ
Score Cytoplasm Nucleus Cytoplasm and nucleus
n (%) n (%) n (%)
0 2 (0.7) 125 (41.4) 2 (0.7)
1 1 (0.3) 0 (0.0) 1 (0.3)
2 1 (0.3) 16 (5.3) 1 (0.3)
3 67 (22.2) 76 (25.2) 58 (19.2)
4 13 (4.3) 28 (9.3) 14 (4.6)
6 142 (47.0) 50 (16.6) 119 (39.4)
9 76 (25.2) 7 (2.3) 107 (35.4)
Total 302 (100.0) 302 (100.0) 302 (100.0)Page 6 of 9
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(unpublished data). 14-3-3σ methylation in all normal
blood samples and vulvar carcinomas may be due to the
normal lymphocytes in blood and the lymphocytes sur-
rounding the epithelial tumors. Previously, Bhatia et al
[36] have demonstrated 14-3-3σ gene to be methylated in
normal lymphocytes. Therefore, methylation identified
within 14-3-3σ gene in some of the vulvar carcinomas
reported by Gasco et al [25] may be due to inflammatory
cells surrounding cancer cells [37]. Despite this problem,
the low level of 14-3-3σ protein expression in a relative
high number of vulvar carcinomas indicates that loss of
14-3-3σ expression may be important in the pathogenesis
of a subset of vulvar squamous cell carcinoma.
Interestingly, we found different subcellular distribution
of 14-3-3σ protein in cells in normal tissues and in cancer
tissues. The high 14-3-3σ expression in cytoplasm but not
in nucleus was found in all the 11 normal tissues,
whereas, in vulvar carcinomas 72% and 59% of the cases
had high expression of 14-3-3σ in cytoplasm and nucleus,
respectively. Previously, Van Hermet and coworkers [38]
showed that 14-3-3σ was mainly localized in the cyto-
plasm and only in lower levels present in the nucleus,
which is consistent with subcellar distribution of the pro-
tein in normal vulvar cells. The cytoplasmic localization
of 14-3-3σ protein in normal vulvar cells may prevent cyc-
lin B1-CDC2 complex from entering the nucleus and ini-
tiate mitosis [14,39]. In the present work we have found
in vulvar carcinoma cells that more 14-3-3σ protein
moved from cytoplasm to nucleus and stayed there. This
might imply that 14-3-3σ have less power to sequester
cyclin B1-CDC2 complex in cytoplasm by its nucleus
translocation, as a result cell fails to be arrested at G2
checkpoint, but enters into cell division. [14] Nuclear
location of 14-3-3σ protein may thus play a role in tum-
origenesis of vulvar squamous cell carcinomas. However,
we found that high expression of 14-3-3σ in cytoplasm as
well as in nucleus was significantly correlated to large
tumor diameter and deep of invasion. Furthermore, nei-
ther 14-3-3σ expression in cytoplasm nor in nucleus was
significant associated with clinical outcome. These results
may indicate that the cellular localization of 14-3-3σ is
not important for the progression of vulvar carcinomas.
However, we cannot exclude the possibility that nuclear
localization of 14-3-3σ protein may be an early event in
carcinogenesis of vulvar carcinomas. Further studies are
needed to clarify the importance of 14-3-3σ nuclear local-
ization in development of vulvar carcinomas.
In our study, we found that high 14-3-3σ protein expres-
sion in cytoplasm, nuclear, and both cytoplasm/nuclear
was significant correlated with large tumor diameter and
deep invasion. This is in disagreement with the findings in
colorectal carcinomas [24] and gastric carcinomas [40],
where 14-3-3σ protein expression did not correlate with
tumor size.
For the first time, 14-3-3σ protein expression and its prog-
nostic importance has been examined in vulvar squamous
cell carcinomas. No significant association was found
between disease-specific survival and 14-3-3σ expression,
which was in line with the findings in breast carcinomas
[22]. However, in breast carcinomas 14-3-3σ cytoplasmic
subcellular localization showed a statistically significant
correlation with survival in univariate analysis, but not in
Expression of 14-3-3σ mRNA in vulvar carcinomas and vul-var c ll linesFigure 2
Expression of 14-3-3σ mRNA in vulvar carcinomas 
and vulvar cell lines. Expression of 14-3-3σ mRNA in vul-
var carcinomas (no.1–11), vulvar carcinoma cell lines SW-
954 (no.12) and CAL-39 (no.13).
Table 3: Relative risk (RR) of dying from vulvar cancer
Variable Grouping Ratio of risk (RR) 95% CI p
FIGO 1a vs 1b vs II vs III vs IV 1.86 1.18–2.9 0.007
Lymph nodes metastsis Absent vs Present 1.49 1.00–2.23 0.05
Age 25–69 yrs vs 70–84 yrs vs = 85 yrs 1.10 1.00–1.04 0.05
Depth of invasion 0.0–4.0 mm vs 4.1–8.0 mm vs 8.1–35.0 mm 1.82 1.13–2.94 0.01Page 7 of 9
(page number not for citation purposes)
BMC Cancer 2008, 8:308 http://www.biomedcentral.com/1471-2407/8/308multivariate analysis [22]. Previously, loss of the 14-3-3σ
protein expression was correlated with poor prognosis in
epithelial ovarian cancer in univariate analysis, but not in
multivariate analysis [41]. Patients with endometrial ade-
nocarcinoma absence of 14-3-3σ protein expression had a
shorter overall survival in multivariate analysis [23]. In
contrast to these findings, Perathoner et al [24] found that
in colorectal carcinoma patients increased expression of
14-3-3σ protein were associated with poor survival in
multivariate analysis. Taken together, these studies indi-
cate that the role of 14-3-3σ is cancer specific.
In the present work, 14-3-3σ was not associated to p53
protein expression, which was similar to the findings in a
variety of cancers from bladder, prostate, endometrium,
ovarium, breast [37] and neuroendocrine lung tumors
[21]. These findings indicate that the expression of 14-3-
3σ may be regulated by other factors than p53.
To our knowledge, the relationship between levels of 14-
3-3σ mRNA and protein expression in vulvar carcinomas
has not been studied previously. Gasco et al [25] found a
marked reduction or a complete absence of 14-3-3σ
mRNA in 20 vulvar carcinomas with CpG methylation.
However, in that study no data of corresponding 14-3-3σ
protein levels were included [25]. In our work, no signifi-
cant association was identified between levels of 14-3-3σ
mRNA and protein expression. This was consistent with
the results in uterine cervical cancer [42] and colon cancer
cell lines [24] where expression of 14-3-3σ mRNA did not
fully correspond to 14-3-3σ protein expression. These
findings indicate that 14-3-3σ expression is also regulated
at the post-transcriptional level. There may be modifica-
tions of mRNA stability and/or translational efficiency
[43], or alternatively, some regulation at the post-transla-
tional level may exist [23,43]. In breast cancer cells post-
translational regulation by estrogen-induced zinc finger
protein, resulting in 14-3-3σ degradation has been
reported [37].
Conclusion
Low levels of 14-3-3σ protein expression in 25% of the
cases may indicate that 14-3-3σ protein expression may
be associated with tumorigenesis in a subset of vulvar
squamous cell carcinomas. However 14-3-3σ protein
expression was not associated with prognosis.
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